We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6383:TSEDaifuku Co., Ltd. Analysis

Data as of 2026-06-11 - not real-time

¥6,379.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Daifuku Co., Ltd. is trading above its long‑term moving average but remains below the shorter‑term averages, indicating a price that is still anchored to a broader uptrend yet facing short‑term pressure. The RSI is hovering in the lower‑mid range, suggesting modest oversold conditions, while the MACD shows a bearish divergence and volume has been trending down, adding to the short‑term downside bias. Despite a solid revenue growth rate and healthy operating margins, the stock appears significantly overvalued relative to its discounted cash‑flow estimate and peers' price‑earnings multiples, and the market’s extreme greed sentiment further amplifies the valuation concern. The dividend yield is modest but the payout ratio is comfortably low, supported by a strong cash position, making the dividend stream sustainable.
From a risk perspective, the stock exhibits high recent volatility yet a relatively low beta, implying that price swings are more company‑specific than market‑driven. Liquidity remains adequate given the large market cap, though the recent decline in trading volume signals a potential softening of investor interest. Overall, the technical setup points to near‑term caution, while the fundamentals suggest a more balanced medium‑term outlook, and the valuation gap leaves room for a longer‑term re‑assessment.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD histogram
  • Price below short‑term SMAs
  • Decreasing trading volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Steady revenue growth and operating margins
  • Sustainable dividend payout
  • Valuation still above fair value but not extreme

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong cash balance and low debt‑to‑equity relative to assets
  • Diversified global customer base reducing geographic concentration
  • Potential for valuation correction aligning price with intrinsic value

Key Metrics & Analysis

Financial Health

Revenue Growth7.80%
Profit Margin11.99%
P/E Ratio31.5
Debt/Equity13.38
P/B Ratio5.1
Op. Cash Flow¥72.9B
Industry P/E30.4

Technical Analysis

TrendBullish
RSI37.2
Support¥6,053.00
Resistance¥7,854.00
MA 20¥6,945.60
MA 50¥6,691.58
MA 200¥5,551.04
MACDBearish
VolumeDecreasing
Fear & Greed Index86.71

Valuation

Fair Value¥3,042.81
Target Price¥7,353.33
Upside/Downside15.27%
GradeOvervalued
TypeGrowth
Dividend Yield1.29%

Risk Assessment

Beta0.78
Volatility47.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.